Our mission is to develop artificial intelligence products and solutions that improve access and quality of diagnosis across areas of life sciences.
Our vision is to be recognized as an innovative technology company with strong research orientation & focus on solving real world problems that have large social and economic impact.
Netra.AI is an comprehensive retinal screening platform powered by artificial intelligence to enable automated diagnosis of preventable blindness conditions quickly with minimum involvement of a specialist.
- Reduce incidence of blindness by timely identification of patients at risk.
- Offer insights to medical practitioners thus enabling improved diagnostic outcome.
NetraScreen ,powered by Netra.AI platform,automates retinal image analysis for identifying preventable blindness conditions such as Diabetic Retinopathy, Diabetic Macular Edema and Glaucoma in an easy , quick and efficient manner with minimum involvement of specialist. NetraScreen is bundled with easy to use cloud based tele medicine web interface.
Diabetic Macular Edema (DME) or Diabetic Maculopathy (DM) is a condition characterized by the appearance of exudates on close to the macula which effects the central vision of the patient . DME usually develops at any time during the progression of Diabetic Retinopathy (DR).NETRA-DME solution which will help in early diagnosis of the disease.
NETRA-DME is under clinical validation with leading ophthalmology hospitals in India.